[ad_1]
Doctors and vaccine manufacturers are concerned. What if the sera that are currently available will no longer be effective against the new strains? Specialists are working on new versions of the vaccines or testing new administration regimens.
For example, the British government is funding CureVac to use artificial intelligence to anticipate which new strains will appear in circulation. They will also do an immunization test with one dose of AstraZeneca and one dose of Pfizer. A minimum of six weeks is the period during which a vaccine for a new strain can be created.
Bloomberg writes that there are two more options: a vaccine that targets multiple strains of coronavirus, such as flu vaccine formulas. Glaxo and CureVac are working on a multi-strain vaccine, which will be ready only next year.
Another variant of the vaccine is a serum that produces antibodies not only against the coronavirus spike protein, but also against its core proteins. A British company has already done well with such a vaccine in mouse studies, and will begin human trials in the summer.
For the most important news of the day, broadcast in real time and presented equally, like our Facebook page!
Follow Mediafax on Instagram to see amazing images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your information and personal use. Is forbidden republish the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, contact us at [email protected].
[ad_2]
